...immune-suppressing into tumor-suppressing agents.The Palo Alto-based company was co-founded by serial entrepreneur Guo-Liang Yu, an OrbiMed...

...Bioscience in 2016, has raised at least $239 million in venture money from investors including OrbiMed...
...Merchant Bank and Ping An Ventures. Co-founder and CEO Yu is a venture partner at OrbiMed...

...developmentYisheng Biopharma Co. Ltd. raised $130 million in a series B round co-led by Oceanpine and OrbiMed...

...oversubscribed series C round co-led by GL Ventures and Temasek. New investors Oceanpine Capital and OrbiMed...

...September from an investor syndicate that included Pontifax, OrbiMed...

...sole investor in the company’s 2016 A round, also participated in the series C alongside OrbiMed...

...By Gunjan ohri, data content analyst OrbiMed Advisors continued to lead the pack in terms of...
...VCs by number of biotech deals each participated in at least 30 rounds from 2015-20. OrbiMed...
...number of venture rounds of any series, and excludes venture debt.  Source: BioCentury’s BCIQ database Gunjan Ohri OrbiMed...

...as bigger players consolidate via M&A and prepare for commercial launch.Delfi Diagnostics Inc. raised an OrbiMed-led...
...studies to detect specific cancers like lung cancer in high-risk individuals. In addition to leader OrbiMed...

...development of its endocrinology therapies in Greater China. Sequoia China led the round with participation from OrbiMed...

...Also participating in the series B were Surveyor Capital, Invus, Wellington Management Co., Nexttech Invest, OrbiMed...
...Epidermal growth factor receptor 2 BC Staff CVnCoV CT-0508 (CARMA-0508) ARGX-113 (efgartigimod) Bayer AG CureVac N.V. Boxer Capital EcoR1 Capital Omega Funds Vida Ventures Surveyor Capital Invus Wellington Management OrbiMed Casdin...